Outcomes of buprenorphine maintenance in office-based practice

被引:28
|
作者
Magura, Stephen
Lee, Stephen J.
Salsitz, Edwin A.
Kolodny, Andrew
Whitley, Susan D.
Taubes, Tanaquil
Seewald, Randy
Joseph, Herman
Kayman, Deborah J.
Fong, Chunki
Marsch, Lisa A.
Rosenblum, Andrew
机构
[1] Natl Dev & Res Inst Inc, New York, NY 10010 USA
[2] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
[3] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
关键词
buprenorphine; opioids; substance misuse; office-based treatment; drug dependence treatment; OPIOID DEPENDENCE; PSYCHIATRIC-DIAGNOSIS; HEROIN DEPENDENCE; CONTROLLED TRIAL; OPIATE ADDICTS; METHADONE; COMORBIDITY; ABUSE;
D O I
10.1300/J069v26n02_03
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Buprenorphine is an efficacious treatment for opioid dependence recently approved for office-based medical practice. The purpose of the study was to describe the background characteristics, treatment process, outcomes and correlates of outcomes for patients receiving buprenorphine maintenance in "real world" office-based settings in New York City, without employing the many patient exclusion criteria characterizing clinical research studies of buprenorphine, including absence of co-occurring psychiatric and non-opioid substance use disorders. A convenience sample of six physicians completed anonymous chart abstraction forms for all patients who began buprenorphine induction or who transferred to these practices during 2003-2005 (N = 86). The endpoint was the patient's current status or status at discharge from the index practice, presented in an intent-to-treat analysis. The results were: male (74%); median age (38 yrs); White, non-Hispanic (82%); employed full-time, (58%); HCV+ (15%); substance use at intake: prescription opioids (50%), heroin (35%), non-opioids (49%); median length of treatment (8 months); median maintenance dose (15 mg/day); prescribed psychiatric medication (63%). The most frequent psychiatric disorders were: major depression, obsessive-compulsive and other anxiety, bipolar. At the endpoint: retained in the index practice (55%); transferred to other buprenorphine practice (6%); transferred to other treatment (7%); lost to contact or out of any treatment (32%). Outcomes were positive, in that 2/3 of patients remained in the index practice or transferred to other treatment. Patients living in their own home or misusing prescription opioids (rather than heroin) were more likely, and those employed part-time were less likely, to be retained in the index practice. At the endpoint, 24% of patients were misusing drugs or alcohol. Co-occurring psychiatric disorders and polysubstance abuse at intake were common, but received clinical attention, which may explain why their effect on outcomes was minimal.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 50 条
  • [21] BUPRENORPHINE TREATMENT OUTCOMES AMONG PATIENTS WITH HOME- VERSUS OFFICE-BASED INDUCTIONS
    Cunningham, Chinazo
    Roose, Robert
    Sohler, Nancy
    Kunins, Hillary
    Giovanniello, Angela
    Li, Xuan
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2010, 25 : 234 - 234
  • [22] Buprenorphine for Office-Based Treatment of Patients With Opioid Addiction
    Manlandro, James J., Jr.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2005, 105 (06): : S8 - S13
  • [23] Prior criminal charges and outcomes among individuals initiating office-based buprenorphine treatment
    Elizabeth E Harris
    Janet S Jacapraro
    Darius A Rastegar
    Health and Justice, 1 (1):
  • [24] Public sector low threshold office-based buprenorphine treatment: outcomes at year 7
    Bhatraju, Elenore Patterson
    Grossman, Ellie
    Tofighi, Babak
    McNeely, Jennifer
    DiRocco, Danae
    Flannery, Mara
    Garment, Ann
    Goldfeld, Keith
    Gourevitch, Marc N.
    Lee, Joshua D.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2017, 12
  • [25] Handbook of Office-Based Buprenorphine Treatment of Opioid Treatment
    Liberto, Joseph G.
    PSYCHIATRIC SERVICES, 2012, 63 (05) : 515 - 515
  • [26] Public sector low threshold office-based buprenorphine treatment: outcomes at year 7
    Elenore Patterson Bhatraju
    Ellie Grossman
    Babak Tofighi
    Jennifer McNeely
    Danae DiRocco
    Mara Flannery
    Ann Garment
    Keith Goldfeld
    Marc N. Gourevitch
    Joshua D. Lee
    Addiction Science & Clinical Practice, 12
  • [27] Office-based buprenorphine: Results in three treatment settings
    Ling, W
    Miotto, K
    Rathner, J
    Sodano, R
    Samiy, T
    Ho, W
    Fradis, J
    Sena, D
    Maya, S
    JOURNAL OF ADDICTIVE DISEASES, 2001, 20 (02) : 153 - 153
  • [28] Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence
    Weinstein, David D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (02) : 256 - 256
  • [29] Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence
    Balon, Richard
    ANNALS OF CLINICAL PSYCHIATRY, 2013, 25 (01) : 74 - 76
  • [30] Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients
    Abraham, Rohit
    Wilkinson, Elizabeth
    Jabbarpour, Yalda
    Petterson, Stephen
    Bazemore, Andrew
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2020, 33 (01) : 9 - 16